Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1

Abstract

A B S T R A C T PurposeThe characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated. MethodsPatients receiving weekly paclitaxel (70 to 90 mg/m 2 ) completed daily questionnaires and weekly European Organisation for Research and Treatment of Cancer (EORTC) Chemotherapy-Induced Peripheral Neuropathy (CIPN) -20 instruments during the entire course of therapy.Results P-APS symptoms peaked 3 days after chemotherapy. Twenty percent of patients had pain scores of 5 to 10 of 10 with the first dose of paclitaxel. Sensory neuropathy symptoms were more prominent than were motor or autonomic neuropathy symptoms. Of the sensory neuropathy symptoms, numbness and tingling were more prominent than was shooting or burning pain. Patients with higher P-APS pain scores with the first dose of paclitaxel appeared to have more chronic neuropathy. ConclusionThese data support that the P-APS is related to nerve pathology as opposed to being arthralgias and/or myalgias. Numbness and tingling are more prominent chronic neuropathic symptoms than is shooting or burning pain.

The Vitamin E Preventive Effect on Taxol-Induced Neuropathy Among Patients With Breast Cancer: A Randomized Clinical Trial

“…Vitamin E is an important fat-soluble antioxidant that may play a role in the prevention of CIPN progression. The findings of our study fully support this hypothesis, but another point receiving considerable attention is that Taxol leads more to sensory neuropathy than to motor or autonomic nerve dysfunction (13,14). This suggests a high degree of inhibitory effect for vitamin E on CIPN, especially due to Taxol treatment in breast cancer.…”

OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity

“…This acute syndrome is possibly caused by activation of Toll-like receptor 4 (TLR4) in the spinal dorsal horn and DRG (7), the main site of paclitaxel uptake within the nervous system (8). Interestingly, prospective clinical studies have demonstrated that patients experiencing the acute pain syndrome following the first administration of paclitaxel are those who subsequently develop chronic neuropathy (9).…”

Can pregabalin prevent paclitaxel-associated neuropathy?—An ACCRU pilot trial

“…It can also cause an acute pain syndrome, described in up to 58 % of patients [1]. Historically, this syndrome, characterized by subacute onset of aches and pain developing within 1 to 3 days of paclitaxel administration, has been commonly referred to as paclitaxel-induced arthralgias/myalgias [1].…”